Takeda's Launch Cadence: A Pivotal Quarter
As ORZEYFUL, rusfertide, and zasocitinib near the starting line, Takeda's execution sets the stage for Horizon Two.
TAK · Earnings Call · 2026-07-30
Quarter in Focus
Takeda delivered a solid start to fiscal 2026. Core revenue declined a slight 0.5% at constant exchange rates, but FX added ¥118.2 billion, propelling reported revenue up 10.2%. Core operating profit was essentially flat at CER, while core EPS fell 11.8% due to a favorable tax position in the prior year. As Julie Kim said, “We delivered a solid start to the fiscal year, and our performance this quarter demonstrates steady progress against our strategic priorities.” — Julie Kim, CFO · 2026-07-30 The mature portfolio continues to erode, but core in-line brands grew 2.3% CER, and the new launches category (only 4% of revenue) expanded 22.6% CER. The company is executing its transformation program, which is funding investment in R&D and launch readiness. The launch preparation for three transformative medicines is the central focus.Orexin: A New Standard of Care
The most concrete catalyst is ORZEYFUL, a first-in-class orexin agonist for narcolepsy type 1. It received its first approval in China, with US and Japan decisions expected this quarter. Andy Plump highlighted the unprecedented REM latency normalization: “ORZEYFUL shifted mean REM latency into the normative range across all treatment groups.” — Andrew Plump, Chief Medical Officer · 2026-07-30 Beyond efficacy, the company has been preparing the market for over a year: MSLs in the field, payer engagement, specialty pharmacy built. Julie Kim explained the positioning: “We studied it as a monotherapy.” — Julie Kim, CFO · 2026-07-30 This is a potential new standard of care, and the company expects launches in the second half of 2026.Rusfertide and Zasocitinib: Building a Launch Franchise
rusfertide, a hepcidin mimetic for PV, is on track for an August PDUFA and launch. After Protagonist's opt-out, Takeda has global rights. Zasocitinib, a TYK2 inhibitor for psoriasis, posted superiority over deucravacitinib in a head-to-head, with >35% PASI 100 at week 16. The launch cadence is dense—three launches in under a year—and the company is already scaling up commercial infrastructure. These launches are expected to be the bridge to Horizon Two growth.Pipeline Depth and Financial Discipline
Beyond the three near-term assets, the pipeline includes TAK-928 (PD-1/IL-2 bispecific) with encouraging OS data, elritercept in MDS, and TAK-921 in gastric cancer. The transformation program is on track to deliver ~¥100 billion in savings this year, funding these investments. CFO Milano Furuta noted that gross margin improved on transactional FX and a one-time milestone, but full-year guidance remains. The company is balancing growth investments with margin protection.Outlook and Capital Markets Day
Management reaffirmed guidance and announced a Capital Markets Day on December 11. As Julie Kim said,The market will be watching the launch execution closely. Prior quarters have set the stage: Milano said in May, “2027 and beyond for that period, we want to be back to growth.” — Milano Furuta, CFO or Finance Executive · 2026-05-13 And Julie added, “Horizon One is a 2- to 3-year time frame.” — Julie Kim, Executive or Senior Management · 2026-05-13 This quarter's results put Takeda firmly on track for that trajectory. The real test will be the transformation program's payoff—if ORZEYFUL and rusfertide meet expectations, Takeda will have the growth engine it needs to transition from transformation to acceleration, finally unlocking Horizon Two.We are delivering on our priorities in Horizon One towards a clear set of operational and financial goals.